drugset / Trial / NCT00194012
Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder
Phase 3
Completed
62 enrolled
University Hospitals Cleveland Medical Center
Bristol-Myers Squibb · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to test the effectiveness and tolerability/safety of aripiprazole (Abilify) in children with subsyndromal symptoms of bipolar disorder who also have a parent with bipolar disorder and other family member with a mood disorder.
Timeline
- Start
- 2004-08
- Primary completion
- 2012-05
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aripiprazole | Other / unclassified | 2 mg | — |
| Comparator | Aripiprazole | Other / unclassified | 5 mg | — |
| Comparator | Aripiprazole | Other / unclassified | 7 mg | — |
| Comparator | Aripiprazole | Other / unclassified | 10 mg | — |
| Comparator | Aripiprazole | Other / unclassified | 12 mg | — |
| Comparator | Aripiprazole | Other / unclassified | 15 mg | — |